(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 33.22% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.64%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.15%.
Cytosorbents's revenue in 2026 is $34,352,442.On average, 5 Wall Street analysts forecast CTSO's revenue for 2026 to be $2,625,659,579, with the lowest CTSO revenue forecast at $2,485,543,175, and the highest CTSO revenue forecast at $2,756,292,534. On average, 4 Wall Street analysts forecast CTSO's revenue for 2027 to be $3,144,171,921, with the lowest CTSO revenue forecast at $2,900,365,609, and the highest CTSO revenue forecast at $3,365,808,314.
In 2028, CTSO is forecast to generate $5,400,039,753 in revenue, with the lowest revenue forecast at $3,175,574,074 and the highest revenue forecast at $7,715,508,869.